Novartis AG Pre-Tax Profit Margin 2010-2024 | NVS
Current and historical pre-tax profit margin for Novartis AG (NVS) from 2010 to 2024. Pre-tax profit margin can be defined as earnings before taxes as a portion of total revenue. Novartis AG pre-tax profit margin for the three months ending September 30, 2024 was .
| Novartis AG Pre-Tax Profit Margin Historical Data |
| Date |
TTM Revenue |
TTM Pre-Tax Income |
Pre-Tax Margin |
| 2024-09-30 |
$49.94B |
$12.73B |
25.49% |
| 2024-06-30 |
$48.86B |
$10.90B |
22.31% |
| 2024-03-31 |
$47.73B |
$9.73B |
20.39% |
| 2023-12-31 |
$46.66B |
$9.12B |
19.55% |
| 2023-09-30 |
$41.66B |
$7.63B |
18.30% |
| 2023-06-30 |
$40.35B |
$7.66B |
18.98% |
| 2023-03-31 |
$41.69B |
$7.03B |
16.86% |
| 2022-12-31 |
$43.46B |
$7.18B |
16.51% |
| 2022-09-30 |
$50.20B |
$23.25B |
46.31% |
| 2022-06-30 |
$52.79B |
$24.89B |
47.15% |
| 2022-03-31 |
$53.00B |
$26.36B |
49.73% |
| 2021-12-31 |
$52.88B |
$26.14B |
49.43% |
| 2021-09-30 |
$56.14B |
$11.75B |
20.92% |
| 2021-06-30 |
$51.56B |
$10.93B |
21.19% |
| 2021-03-31 |
$49.88B |
$9.71B |
19.46% |
| 2020-12-31 |
$49.90B |
$9.88B |
19.80% |
| 2020-09-30 |
$45.83B |
$9.08B |
19.81% |
| 2020-06-30 |
$49.53B |
$9.08B |
18.32% |
| 2020-03-31 |
$49.93B |
$9.42B |
18.87% |
| 2019-12-31 |
$48.68B |
$8.94B |
18.37% |
| 2019-09-30 |
$47.86B |
$8.51B |
17.79% |
| 2019-06-30 |
$46.76B |
$8.36B |
17.87% |
| 2019-03-31 |
$46.39B |
$13.90B |
29.95% |
| 2018-12-31 |
$46.10B |
$14.10B |
30.58% |
| 2018-09-30 |
$47.37B |
$15.06B |
31.80% |
| 2018-06-30 |
$48.67B |
$15.25B |
31.33% |
| 2018-03-31 |
$49.51B |
$9.39B |
18.97% |
| 2017-12-31 |
$50.14B |
$9.00B |
17.95% |
| 2017-09-30 |
$49.58B |
$7.78B |
15.68% |
| 2017-06-30 |
$49.23B |
$7.61B |
15.47% |
| 2017-03-31 |
$49.41B |
$7.41B |
15.00% |
| 2016-12-31 |
$49.44B |
$7.82B |
15.81% |
| 2016-09-30 |
$49.63B |
$7.87B |
15.86% |
| 2016-06-30 |
$49.78B |
$7.77B |
15.60% |
| 2016-03-31 |
$50.00B |
$7.81B |
15.62% |
| 2015-12-31 |
$50.39B |
$8.13B |
16.14% |
| 2015-09-30 |
$50.94B |
$9.76B |
19.16% |
| 2015-06-30 |
$51.75B |
$11.12B |
21.49% |
| 2015-03-31 |
$52.81B |
$12.11B |
22.94% |
| 2014-12-31 |
$53.63B |
$12.27B |
22.88% |
| 2014-09-30 |
$52.60B |
$11.96B |
22.74% |
| 2014-06-30 |
$52.21B |
$10.92B |
20.91% |
| 2014-03-31 |
$51.54B |
$10.81B |
20.96% |
| 2013-12-31 |
$52.72B |
$10.81B |
20.50% |
| 2013-09-30 |
$49.87B |
$11.02B |
22.10% |
| 2013-06-30 |
$51.00B |
$11.32B |
22.18% |
| 2013-03-31 |
$52.26B |
$11.42B |
21.84% |
| 2012-12-31 |
$51.97B |
$11.24B |
21.62% |
| 2012-09-30 |
$57.49B |
$9.62B |
16.73% |
| 2012-06-30 |
$58.48B |
$9.75B |
16.66% |
| 2012-03-31 |
$59.07B |
$9.86B |
16.69% |
| 2011-12-31 |
$59.38B |
$10.56B |
17.78% |
| 2011-09-30 |
$58.84B |
$11.93B |
20.28% |
| 2011-06-30 |
$56.63B |
$11.82B |
20.87% |
| 2011-03-31 |
$53.43B |
$11.53B |
21.58% |
| 2010-12-31 |
$51.56B |
$11.70B |
22.70% |
| 2010-09-30 |
$50.24B |
$11.97B |
23.83% |
| 2010-06-30 |
$48.71B |
$11.67B |
23.96% |
| 2010-03-31 |
$47.53B |
$11.16B |
23.47% |
| 2009-12-31 |
$45.10B |
$9.92B |
22.00% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$223.511B |
$45.440B |
|
Novartis has one of the strongest and broadest portfolio of oncology drugs and generics. It continues to build depth in 5 core therapeutic areas Cardio-Renal, Immunology, Neuroscience, Oncology and Hematology, strength in technology platforms - Targeted Protein Degradation, Cell Therapy, Gene Therapy, Radioligand Therapy, and xRNA. Novartis efforts to strengthen its wide and deep oncology portfolio by developing breakthrough treatments. Cosentyx, Entresto, Kesimpta, Zolgensma, Kisqali and Leqvio. In March 2015, Novartis acquired certain oncology products and pipeline compounds from Glaxo. In exchange, it sold its non-influenza Vaccines business to Glaxo. Also, the company has spun off the Alcon business into a separate company. In January 2015, Novartis divested its Animal Health division to Lilly. In July 2015, the company divested its influenza vaccines business to CSL Limited. Novartis has also acquired The Medicines Company, adding Leqvio, to its portfolio. Novartis sold its investment in Roche.
|
